Allison McGeer, MD

Dr.
Mt. Sinai Hospital, Canada

Disclosure(s): AstraZeneca: Honoraria; GSK: Honoraria; Merck: Honoraria; Moderna: Honoraria; Novavax: Honoraria; Pfizer: Grant/Research Support, Honoraria; Roche: Honoraria; Seqirus: Grant/Research Support, Honoraria

I am an infectious disease physician and clinical epidemiologist at the Sinai Health System in Toronto, and a Professor of Laboratory Medicine and Pathobiology and in the Dalla Lana School of Public Health at the University of Toronto. My research interests are in surveillance for infectious diseases, antimicrobial resistance and adult immunization.

Poster(s):

• (P-40) Impact of case and control selection on influenza vaccine effectiveness (VE) among adults aged 40 years and older hospitalized with acute respiratory illness (ARI) during 2022-2023 using a test negative design (TND): secondary analysis of the North America multi-specimen study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-397) Rapid Prediction of Genetic Relatedness of Escherichia coli Direct from Critical Care Samples Using Metagenomic Sequencing Paired with Neighbour Typing
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-643) Incidence and Clinical Characteristics of Invasive Group A Streptococcal Infections in Underhoused Adults in Toronto, Canada
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-645) Post-pandemic changes in the epidemiology of invasive pneumococcal disease in adults in Toronto, Canada
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-1290) Invasive group A streptococcal infection in children in Toronto, Canada
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1906) Early COVID-19 and Severity of Subsequent Omicron Infection in Ontario, Canada.
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-2051) Assessing SARS-CoV-2 Correlates Protection from Exposed Household Members: A Prospective Cohort Study (AB-PROTECT Study)
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT